## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.6% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($172.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Digi Power X taps former Oracle and VeriSign leader as CTO**
- Source: Proactive financial news | 20251208T140907 | Bullish | Relevance: 99%
-  Digi Power X (NASDAQ:DGXX, TSX-V:DGX) has appointed Jagan Jeyapaul, a Silicon Valley engineering veteran with experience at Oracle, Equinix, and VeriSign, as its new Chief Technology Officer. Jeyapaul will lead the company's technology roadmap, focusing on its ARMS 200 Tier-3 modular data-center platform and the expansion of AI infrastructure deployments. His expertise in secure, high-availability cloud environments is expected to accelerate Digi Power X's AI infrastructure development and prepare them for AI data processing in 2026.

**2. Invesco Ltd. Raises Position in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251207T152044 | Somewhat-Bullish | Relevance: 98%
-  Invesco Ltd. significantly increased its stake in Quest Diagnostics by 29.9% in the second quarter, now holding 1,658,351 shares worth approximately $297.9 million. Other institutional investors like Vanguard and Norges Bank also boosted their holdings, bringing total institutional ownership to 88.06%. Despite insider selling, Quest Diagnostics beat Q3 earnings and revenue estimates and holds a consensus analyst rating of "Moderate Buy" with an average price target of $196.31.

**3. Marshall Wace LLP Reduces Position in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251208T114309 | Neutral | Relevance: 98%
-  Marshall Wace LLP significantly reduced its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 57.6% in Q2, selling 278,204 shares and now holding 205,083 shares valued at approximately $36.84 million. Despite this, Quest Diagnostics exceeded quarterly expectations with $2.60 EPS and $2.82 billion in revenue, also announcing a quarterly dividend of $0.80 and setting FY2025 EPS guidance. The company has a "Moderate Buy" consensus rating from analysts, with a target price of $196.31.

**4. California Public Employees Retirement System Reduces Stake in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251209T101905 | Neutral | Relevance: 98%
- The California Public Employees Retirement System (CalPERS) has reduced its stake in Quest Diagnostics (NYSE:DGX) by 17.3% during the second quarter, selling 85,008 shares and holding 406,276 shares worth $72.98 million. Despite this, institutional investors and hedge funds still own 88.06% of the stock. Analysts have a "Moderate Buy" rating for Quest Diagnostics with an average price target of $196.31, while company insiders have recently sold over 94,000 shares.

**5. Precision oncology at your community’s doorstep**
- Source: Illumina | 20251208T151032 | Somewhat-Bullish | Relevance: 67%
-  Illumina is making comprehensive genomic profiling (CGP) testing more accessible to community cancer care centers. This allows in-house labs to utilize CGP, which assesses hundreds of genes and biomarkers, to improve therapeutic options and patient outcomes. The move aims to decentralize CGP testing, reducing turnaround times and operational barriers for local oncology practices.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $8.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 17.3x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.1B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 17.3 |
| Current P/E | 18.3 |
| YoY Growth | 5.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.8% to -3.6% (+1.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.6pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). MACD histogram bearish (-1.01), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.58% (CS: 18) | Weak |
| RSI_14 | 39.8 | Neutral |
| MACD Histogram | -1.01 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 1.015x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $179.62
- **Stop Loss:** $172.64 (3.9% risk)
- **Target:** $186.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 42
- **Position Value:** $7,544.04
- **Portfolio %:** 7.54%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*